Mycoplasma contamination is the most insidious problem in cell culture. Unlike bacteria or fungi, which announce themselves with turbidity, pH shifts, or visible colonies, mycoplasma infection is completely invisible. These wall-less organisms can reach concentrations of 107–108 per milliliter without causing any change visible to the naked eye or under standard light microscopy. The result is silent data corruption: altered gene expression, shifted glycosylation profiles, depleted nutrients, and compromised product quality across weeks or months of experiments before anyone notices. This guide covers everything a cell culture scientist needs to know about mycoplasma, from detection method selection and regulatory compliance to elimination protocols and evidence-based prevention.
What Is Mycoplasma and Why Is It a Silent Threat?
Mycoplasma are the smallest self-replicating organisms known to science, measuring 0.2–0.8 µm in diameter. They belong to the class Mollicutes (Latin for "soft skin"), a name that reflects their most distinctive feature: the complete absence of a rigid cell wall. This single characteristic explains nearly everything about why mycoplasma is such a persistent problem in cell culture.
Without a cell wall, mycoplasma organisms pass through 0.2 µm sterile filters that effectively remove bacteria and fungi. Standard antibiotics that target cell wall synthesis, including penicillin and its derivatives, have zero effect on mycoplasma. The organisms are also too small to be resolved by standard inverted light microscopy at the magnifications used during routine cell culture work (40–200×). They do not cause turbidity, and they do not produce the pH shifts characteristic of bacterial contamination because their metabolic byproducts are different.
The mycoplasma genome is among the smallest of any self-replicating organism, typically 580–1,350 kb. This minimal genome means mycoplasma organisms are metabolically dependent on their host cells for amino acids (particularly arginine and glutamine), nucleotide precursors, lipids, and cholesterol. They attach directly to the host cell membrane surface via specialized tip structures and consume these nutrients in competition with your cells. Mycoplasma do not typically lyse cells or trigger the obvious cytopathic effects associated with viral or bacterial infection. Instead, they establish a chronic, parasitic relationship that subtly shifts host cell biology in ways that contaminate data without raising alarms.
There are approximately 200 recognized Mollicutes species, but only a handful routinely contaminate cell cultures. The biology of these organisms explains why they are so difficult to eradicate once established: rapid doubling times (1–6 hours for some species), resistance to standard cell culture antibiotics, ability to survive brief exposure to trypsin during passaging, and stability in frozen cell banks at −80°C and in liquid nitrogen.
How Common Is Mycoplasma Contamination?
Mycoplasma contamination is far more prevalent than most researchers expect. Published surveys consistently report that 15–35% of continuous cell cultures in research laboratories worldwide are contaminated, and the number can reach 65–80% in extreme cases where routine screening is absent. The FDA tested over 20,000 cell cultures submitted for regulatory review and found 15% contaminated with mycoplasma. A study by Drexler and Uphoff found that 11% of RNA-seq datasets in the NCBI database contained mycoplasma sequences, meaning contaminated data has propagated into public genomic repositories.
Contamination rates vary dramatically by culture type. Primary cultures freshly isolated from tissue have approximately 1% mycoplasma prevalence. Early passage cultures (passages 1–10) show rates around 5%. Continuous cell lines maintained for months or years reach the widely cited 15–35% range. The difference reflects both accumulated exposure time and the fact that continuous passaging provides repeated opportunities for introduction via contaminated reagents, shared equipment, or aerosol transfer from nearby infected cultures.
The Six Species That Account for 95% of Cases
Despite hundreds of Mollicutes species existing in nature, just six account for approximately 95% of all cell culture mycoplasma contamination events. Their origins provide direct clues about likely introduction routes in your laboratory.
| Species | Prevalence | Origin | Primary Introduction Route | Key Characteristics |
|---|---|---|---|---|
| M. orale | 34% | Human oral cavity | Lab personnel talking/breathing over cultures | Most common species; strict aseptic technique prevents introduction |
| M. hyorhinis | 26% | Bovine/porcine | Contaminated FBS or trypsin | Some strains fail to grow on standard mycoplasma agar; culture method may miss |
| M. arginini | 21% | Bovine | Contaminated FBS or serum supplements | Depletes arginine from media; impairs T-cell proliferation assays |
| M. fermentans | 13% | Human urogenital/respiratory | Lab personnel; contaminated cell lines | Co-stimulates cytokine production; major confounder in immunology research |
| M. hominis | ~3% | Human urogenital | Lab personnel; contaminated cell lines | Less common but clinically significant; hydrolyzes arginine |
| A. laidlawii | ~3% | Environmental (ubiquitous) | Environmental; equipment surfaces; media | Unique: can grow without sterols; survives broader conditions than Mycoplasma spp. |
The dominance of M. orale (34% of all contaminations) is a clear signal that laboratory personnel are the primary introduction vector. M. orale is a commensal of the human oral cavity, and its presence in a culture almost always traces back to talking, coughing, or breathing over open vessels. The second and third most common species, M. hyorhinis and M. arginini, originate from bovine sources. This points directly to fetal bovine serum as the other major entry point. While modern serum suppliers gamma-irradiate or triple-filter their products, historically contaminated lots have been well documented, and not all suppliers maintain equivalent quality standards.
How Does Mycoplasma Affect Your Research and Product Quality?
Mycoplasma contamination does not merely coexist with your cells. It fundamentally alters their biology in ways that corrupt experimental data and compromise biopharmaceutical product quality. The effects are systemic, dose-dependent, and often irreversible without clearing the infection.
Biopharmaceutical Product Quality
The most rigorous study of mycoplasma impact on biopharmaceutical quality was published by Fratz-Berilla et al. (2020), who deliberately contaminated CHO cell bioreactors producing a monoclonal antibody. The results were striking:
- Glycosylation shifts: High mannose glycoforms reached 16.2–17.4% in contaminated cultures versus minimal levels in clean controls. This is a critical quality attribute (CQA) because high mannose species have altered pharmacokinetics and reduced Fc effector function.
- Purity collapse: Antibody purity dropped from 96.2% to 56.3% as measured by SEC-HPLC, reflecting increased aggregation and degradation products.
- Charge heterogeneity: Acidic charge variants increased substantially, indicating chemical modifications (deamidation, oxidation) triggered by the mycoplasma-altered culture environment.
These quality changes would cause any GMP batch to fail release testing. In a commercial manufacturing context, a single mycoplasma contamination event detected at bulk harvest could result in batch losses worth millions of dollars.
Research Data Integrity
Mycoplasma contamination corrupts research data through multiple mechanisms. In proteomics, 18.7% of proteins show significantly altered expression between mycoplasma-infected and clean cultures. In growth studies, mycoplasma competes for nutrients and can either inhibit or stimulate proliferation depending on the species and cell type. Specific effects include:
- Nutrient depletion: M. arginini hydrolyzes arginine via the arginine dihydrolase pathway, depleting a key amino acid. Other species consume glutamine, nucleotide precursors, and fatty acids from the medium.
- Cytokine interference: Mycoplasma lipoproteins activate TLR2/TLR6 signaling, stimulating or suppressing cytokine secretion. This makes any immunology experiment in contaminated cultures unreliable.
- Chromosomal aberrations: Chronic mycoplasma infection causes chromosomal damage, including translocations and aneuploidies, that permanently alter the karyotype of the host cell line.
- Gene expression changes: Microarray and RNA-seq studies show widespread transcriptomic shifts in contaminated cells, affecting stress response, metabolism, and signal transduction pathways.
- Apoptosis modulation: Depending on species, mycoplasma can either promote or suppress apoptosis, confounding any assay that relies on cell death as a readout.
The 11% contamination rate found in NCBI RNA-seq datasets by Drexler et al. means that published, peer-reviewed genomic data has been corrupted by mycoplasma at scale. If your cell lines are not routinely screened, every experiment based on them is potentially compromised.
Fit Growth Curves to Detect Subtle Growth Changes
Mycoplasma can subtly alter growth kinetics. Fit your time-course data to logistic, Gompertz, and Baranyi models to detect shifts in growth rate or lag time that may signal contamination.
Detection Methods Compared: PCR, Culture, Staining, and Enzymatic Assays
qPCR is the recommended first-line method for routine mycoplasma screening, offering the best combination of speed (2–4 hours), sensitivity (1–10 CFU/mL), and species coverage (~150 Mollicutes species). However, no single method is perfect. The table below compares all five widely used mycoplasma detection approaches across the parameters that matter most for method selection.
| Method | Time to Result | LOD (CFU/mL) | Species Coverage | Key Advantage | Key Limitation |
|---|---|---|---|---|---|
| qPCR / PCR | 2–4 hours | 1–10 | ~150 Mollicutes spp. (16S rRNA primers) | Speed + sensitivity + broad coverage | Detects dead mycoplasma (DNA persists); potential for PCR inhibitors in complex matrices |
| Microbiological culture | 28 days | 1 | Most cultivable species | Gold standard; detects only viable organisms | Very slow; some M. hyorhinis strains fail to grow on standard agar; fastidious species missed |
| DAPI / Hoechst 33258 staining | ~30 min | ~104 | All DNA-containing organisms | Visual confirmation; cheap; orthogonal to PCR | Low sensitivity; requires fluorescence microscope; reader-dependent |
| MycoAlert enzymatic assay | 15–20 min | ~100 | Most mycoplasma spp. (enzyme-dependent) | Fastest; no special equipment; plate-reader compatible | Cannot speciate; dead cells give false negatives; cell debris can cause false positives |
| FISH | 2–3 hours | ~103 | Probe-dependent (can be broad or species-specific) | Combines detection with localization; confirms attachment to host cells | Requires fluorescence microscope; moderate sensitivity; specialized probes needed |
Choosing the Right Method for Your Setting
Routine research lab screening: qPCR every 2–4 weeks on all active cultures. Supplement with DAPI/Hoechst staining quarterly as an orthogonal check. This two-method approach minimizes both false negatives (PCR is highly sensitive) and false positives (staining provides visual confirmation).
GMP manufacturing: Both qPCR and microbiological culture are typically required at key process stages. The 28-day culture method is still mandated by some regulators as the definitive test, but USP <77> (effective October 2026) will permit NAT-based (PCR) methods as standalone release tests with validated sensitivity of ≤10 CFU/mL.
Incoming cell line quarantine: Test by qPCR on receipt, then re-test after 3–5 days of antibiotic-free culture. Some mycoplasma species grow slowly, and low-level contaminations may not reach PCR detection thresholds immediately after thawing.
Worked Example: Cost Per Culture Per Year by Detection Strategy
A laboratory maintains 15 active cell lines and screens monthly. Here is the annual cost by method:
qPCR (monthly): 15 lines × 12 months × $15/test = $2,700/year
MycoAlert (monthly): 15 × 12 × $8/test = $1,440/year
DAPI staining (quarterly): 15 × 4 × $3/test = $180/year
Culture method (annual, GMP): 15 × 1 × $85/test = $1,275/year
Recommended combo (qPCR monthly + DAPI quarterly) = $2,880/year
Cost of one undetected mycoplasma event = $20,000–100,000+
ROI: 7–35× return on investment
Regulatory Requirements for Mycoplasma Testing
Regulatory mycoplasma testing requirements are tightening globally, with a clear trend toward accepting nucleic acid testing (NAT) methods alongside or in place of traditional culture methods. Three compendial chapters govern mycoplasma testing for biopharmaceuticals.
USP <63> Mycoplasma Tests (Current)
USP <63> is the current United States Pharmacopeia chapter governing mycoplasma testing. It specifies two methods: (1) a 28-day culture method using both broth and agar media, and (2) an indicator cell culture method using Vero cells with DNA staining. Both methods are required for GMP release testing of biologics. The culture method remains the definitive reference standard, but its 28-day turnaround time creates significant bottlenecks in manufacturing timelines.
EP 2.6.7 Mycoplasmas (Revised April 2026)
European Pharmacopoeia chapter 2.6.7, revised effective April 1, 2026, has been updated to explicitly include NAT-based methods as an alternative to culture. The revision reflects over a decade of regulatory experience with validated PCR assays in European GMP facilities. NAT methods must demonstrate equivalence or superiority to culture methods in terms of sensitivity, specificity, and range of detectable species. The EP revision harmonizes European requirements with the global trend toward faster, more sensitive molecular detection.
USP <77> NAT-Based Testing (Effective October 1, 2026)
The most significant regulatory development in mycoplasma testing is USP <77>, which takes effect on October 1, 2026. This new chapter permits NAT-based testing (qPCR or equivalent) as a standalone method for mycoplasma detection. Key requirements include:
- Sensitivity: The NAT method must achieve a limit of detection of ≤10 CFU/mL or fewer than 100 genomic copies/mL.
- Specificity: Broad-range primers targeting conserved regions (typically 16S rRNA) that detect all clinically relevant Mollicutes species.
- Validation: Method validation must include spiking studies with representative mycoplasma species, matrix interference evaluation, and robustness testing.
GMP Testing Points
Regardless of the detection method chosen, GMP regulations require mycoplasma testing at defined stages of the manufacturing process:
| Testing Point | Material Tested | Typical Method | Rationale |
|---|---|---|---|
| Master Cell Bank (MCB) | Representative vials from banking campaign | Culture + NAT | Certify the source material is mycoplasma-free |
| Working Cell Bank (WCB) | Representative vials after expansion | Culture + NAT | Confirm no contamination introduced during expansion and banking |
| End of Production (EOP) | Cells harvested at end of production bioreactor run | NAT (under USP <77>) | Verify the production culture remained clean through the entire run |
| Bulk Harvest | Unprocessed bulk harvest before purification | NAT or culture | Release testing gate before downstream processing |
Plan Your Cell Bank with QC Vial Allocation
Calculate how many vials to allocate for mycoplasma testing, sterility, identity, and viability QC during your MCB/WCB banking campaign.
How to Eliminate Mycoplasma from Contaminated Cultures
Mycoplasma can be eliminated from contaminated cultures, but not all treatments are equally effective. A 2019 study by Molla Kazemiha et al. compared five antimicrobial treatments across multiple contaminated cell lines and found significant differences in cure rate, regrowth rate, and cell toxicity. The following data, combined with the earlier Uphoff et al. (2012) study, provides the most comprehensive treatment efficacy comparison available.
| Treatment | Mechanism | Cure Rate | Regrowth Rate | Cell Death Rate | Duration |
|---|---|---|---|---|---|
| Plasmocure | Proprietary (dual-target) | 91% | 3% | 6% | 2 weeks |
| BM-Cyclin | Macrolide + tetracycline (protein synthesis) | 70% | 17% | 13% | 2–3 weeks (alternating 3-day cycles) |
| Plasmocin | Macrolide + quinolone (protein synthesis + DNA replication) | 66% | 12% | 22% | 2 weeks (25 µg/mL) |
| MycoRAZOR | Peptide-based | 55% | 42% | 3% | 1 week |
| Enrofloxacin | Fluoroquinolone (DNA gyrase inhibitor) | 15% | 83% | 2% | 2 weeks |
The data clearly shows Plasmocure as the first-choice treatment, with the highest cure rate (91%) and lowest regrowth (3%). BM-Cyclin is the second-best option, achieving 70% cure with moderate regrowth and cell death. Plasmocin has been widely used historically and Uphoff et al. reported an 84% cure rate when backup frozen cells were available for restart after treatment failure, which explains why many laboratories still consider it effective. MycoRAZOR has low cell toxicity (3%) but an unacceptably high regrowth rate (42%), suggesting it suppresses rather than eliminates mycoplasma. Single fluoroquinolones like enrofloxacin and sparfloxacin (33% cure) should not be used as monotherapy.
Treatment Protocol: Step-by-Step
Worked Example: Mycoplasma Elimination from a CHO Producer Clone
A CHO-K1 clone producing a biosimilar mAb tests mycoplasma-positive by qPCR. No clean backup vial is available. Here is the recommended elimination protocol:
Day 0: Confirm positive by independent repeat qPCR
(rule out false positive from DNA carryover)
Day 1: Add Plasmocure at manufacturer-recommended
concentration to all culture media
Day 1–14: Continue normal passaging schedule.
Every media change uses Plasmocure-treated media
Day 14: Remove Plasmocure from all media (washout starts)
Day 21: First post-treatment qPCR (1 week after washout)
Day 28: Second post-treatment qPCR (2 weeks after washout)
Day 35: Third post-treatment qPCR (3 weeks after washout)
IF all three tests NEGATIVE:
→ Declare culture clean
→ Bank 10–20 vials immediately as verified stock
→ Return to routine monthly screening
IF any test POSITIVE:
→ Repeat 14-day treatment (second round)
→ If still positive after round 2: DISCARD culture
Total timeline: 5–7 weeks from detection to verified clean stock
Cost: Treatment ($150–300) + 5 PCR tests ($75) = ~$375 total
Mycoplasma Management Decision Tree
Prevention: A 10-Point Protocol to Keep Cultures Clean
Preventing mycoplasma contamination is far cheaper and more reliable than eliminating it. The 10-point protocol below is based on published best practices from Nikfarjam and Farzaneh (2012) and Drexler and Uphoff (2002), adapted for modern cell culture laboratories.
The combined cost of this 10-point prevention program is modest: qPCR testing kits ($15–30/test), 0.1 µm filters ($2–5 per filtration), and staff training time. Against this, the cost of a single undetected mycoplasma event in a cell line development campaign can easily exceed $50,000 in wasted reagents, repeated experiments, and delayed timelines.
Frequently Asked Questions
How common is mycoplasma contamination in cell culture?
Mycoplasma contamination affects 15–35% of continuous cell cultures worldwide. The FDA tested over 20,000 cultures and found 15% contaminated. Six species account for 95% of cases: M. orale (34%), M. hyorhinis (26%), M. arginini (21%), M. fermentans (13%), M. hominis (~3%), and A. laidlawii (~3%). Primary cultures have ~1% rates, early passage ~5%, and continuous lines 15–35%.
What is the best method to detect mycoplasma in cell culture?
qPCR is the recommended first-line detection method for mycoplasma: it delivers results in 2–4 hours with a limit of detection of 1–10 CFU/mL and covers ~150 Mollicutes species using broad 16S rRNA primers. Microbiological culture (28 days, 1 CFU/mL LOD) remains the gold standard for GMP release testing. For routine lab screening, combine qPCR with periodic fluorescent staining (DAPI/Hoechst 33258) as an orthogonal check.
Can mycoplasma be eliminated from contaminated cell cultures?
Yes. Plasmocure achieves a 91% cure rate with only 3% regrowth and 6% cell death. BM-Cyclin cures 70% of contaminated cultures (17% regrowth, 13% cell death), and Plasmocin achieves 66–84% clearance depending on whether backup frozen cells are available. Post-treatment verification requires three consecutive negative PCR results at weekly intervals after a 2-week antibiotic washout period.
What are the regulatory requirements for mycoplasma testing?
Regulatory mycoplasma testing is governed by USP <63> (Mycoplasma Tests) and EP 2.6.7 (Mycoplasmas, revised April 2026). The new USP <77> (effective October 2026) allows NAT-based testing as a standalone method with a required LOD of ≤10 CFU/mL or fewer than 100 genomic copies/mL. GMP facilities must test at master cell bank, working cell bank, end-of-production, and bulk harvest stages.
How does mycoplasma contamination affect research results and biopharmaceutical product quality?
Mycoplasma contamination fundamentally alters cell behavior and product quality. In CHO bioreactors, mycoplasma increases high mannose glycoforms to 16.2–17.4% versus minimal in clean cultures, drops antibody purity from 96.2% to 56.3%, and increases acidic charge variants. It also depletes arginine and glutamine from media, causes chromosomal aberrations, alters cytokine secretion, and changes expression of 18.7% of proteins. In published datasets, 11% of NCBI RNA-seq submissions were found contaminated with mycoplasma.
Related Tools
- Cell Bank Calculator — Plan MCB/WCB banking campaigns with QC vial allocation for mycoplasma testing, sterility, and identity.
- Growth Curve Fitter — Fit growth curves to logistic, Gompertz, and Baranyi models. Detect subtle growth rate shifts that may signal contamination.
- CellTrack — Track VCD, viability, and metabolites to detect abnormal growth trends early.
- Endotoxin Calculator — Calculate MVD, dilution series, and PPC spike recovery for post-contamination endotoxin verification.
References
- Nikfarjam L, Farzaneh P. Prevention and detection of mycoplasma contamination in cell culture. Cell J. 2012;13(4):203-212. PMID: 23508237
- Uphoff CC, Denkmann SA, Drexler HG. Treatment of mycoplasma contamination in cell cultures with Plasmocin. J Biomed Biotechnol. 2012;2012:267678. doi:10.1155/2012/267678
- Molla Kazemiha V, et al. Effectiveness of Plasmocure in elimination of mycoplasma species from contaminated cell cultures. Cell J. 2019;21(1):70-78. doi:10.22074/cellj.2019.5996
- Fratz-Berilla EJ, et al. Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events. Biotechnol Bioeng. 2020;117(9):2802-2815. doi:10.1002/bit.27436
- Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39(2):75-90. doi:10.1023/A:1022913015916